


Revilico is a software platform company that aims to transform pharmaceutical development by utilizing AI & physics-based algorithms to accelerate the discovery of small molecule drugs.

Team: Asiyah Awais (MTM), Aziz Kamoun (MBA/MEng), Liz Chendo (LLM), Sanggeol (Anthony) Kim (MBA), and Gracie Teed (MEng)

Advisor(s): Viktor Ström, Christian Chung (Revilico Co-Founder), Christopher Korban (Revilico Co-Founder)



Case Study 1


Problem

Address inefficiencies in the early stage drug discovery, an area characterized by **high costs, long turnaround times, and a disconnect between computational predictions and experimental validation**. Further, the first wave of leading AI-enabled have yet to deliver on sweeping promises of reduction in development time and increase in volume. Faster hits are not enough – **value propositions beyond leads and target pipelines are needed to increase success downstream of the preclinical phase.**


Revilico's Software Platform

- **Computational Target Identification:** Utilizing advanced AI and biological insights to uncover precise drug targets.
- **Intelligent Compound Discovery:** Accelerating compound discovery through bioinformatics and high-speed AI screening.
- **Precision-Driven Candidate Refinement:** Combining biological insights with data-driven refinement to refine drug candidates.

Market Potential With Fast-Paced Growth




The AI in drug discovery market is projected to reach USD 35.42 billion by 2034, **growing at a CAGR of 29.6%**. This growth is driven by the **increasing demand for efficient drug development processes, the rising prevalence of chronic diseases, and the higher demand for personalized medicine.**



scRNA Seq Target ID

Redefining the *In Silico* Drug Discovery Value Chain



1. **IP-protected data aggregation** warehousing infrastructure
2. **Virtualized cell platform** to simulate the full biological cascade—from compound binding to gene expression to cellular pathway outcomes
3. **Marketplace for preferred CRO partners** for wet lab validation
4. Distinctive **oncology small molecule** focus empowered by **ever-growing public and proprietary partner-supplied chemical and biological data**

Assessing the Competitive Landscape

- End-to-end AI-enabled leaders like Insitro, BenevolentAI, and Recursion dominate the top right, **offering fully integrated software platforms and automated, high-scale wet labs.**
- Most companies cluster in the mid-AI, pre-clinical zone, indicating a **saturated early-stage market with potential for partnership or consolidation.**

